Sitagliptin in Renal Transplant Recipients

Inclusion criteria

• Renal transplant recipient more than 1 year posttransplant with stable renal function (less than 20% deviation in serum creatinine the last 2 months) and stable prednisolone dose for the last 3 months before inclusion.
• Patients in need of (additional) oral anti-diabetic treatment:

• New onset diabetes patients with fasting plasma glucose 7-8 mmol/ l, and/or 2-hr plasma glucose 12-18 mmol/l after an oral glucose tolerance test (OGTT)
• Patients already on oral hypoglycemic therapy, but with HbA1c 8-11%
• 18 years of age.
• Male patient, or female patient without childbearing potential (surgically sterilized or postmenopausal) or, if female of childbearing potential, is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 Days following discontinuation of the Study Drugs.
• Signed informed consent.

Exclusion criteria

• Treatment with insulin
• Severe liver disease.
• Estimated GFR < 25 ml/min/1.73 m2.
• Skin disorders that may influence laser Doppler flowmetry investigations.
• Pregnant or nursing mothers.